Hospital Pharmacy - July/August 2019 - 231

231

Walker
1072-patient phase III trial, 19.6% of patients treated with
rimegepant were pain-free and 37.6% were free of their most
bothersome symptoms at 2 hours compared with 12% and
25.2% who received placebo. Biohaven Pharmaceuticals
announced that in a 1351-patient phase III trial, 21.2% of
patients treated with rimegepant in an orally dissolving tablet
formulation were pain-free and 35.1% were free of their most
bothersome symptoms at 2 hours compared with 10.9% and
26.8% who received placebo.13
A look at the absolute risk reduction with ubrogepant,
rimegepant, and lasmiditan suggests a benefit over placebo
(Table 1). The drugs have not been compared directly with
an active treatment, so the information in the table is for
reference of what is currently known about the drugs and
does not take into account differences in trial design or
patient populations. These 3 drugs may provide an alternative treatment for acute migraine patients who are intolerant
to triptans.
Author's Note
Information is summarized from selected materials; additional
information may be available from other sources. Due to the preapproval nature of the information, non-peer-reviewed data may be
used. The information provided is meant to provide a way to assess
the development status of a new drug and should not be used in
making patient care decisions.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Scot Walker

https://orcid.org/0000-0002-8527-2560

References
1. Charles A. Migraine. N Engl J Med. 2017;377(6):553-561.
2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML,
Stewart WF. Migraine prevalence, disease burden, and the
need for preventive therapy. Neurology. 2007;68:343-349.

3. Goldberg LD. The cost of migraine and its treatment. Am J
Manag Care. 2005;11(suppl 2):S62-S17.
4. Pringsheim T, Becker WJ. Triptans for symptomatic treatment
of migraine headache. BMJ. 2014;348:g2285.
5. Center for Drug Evaluation and Research. Migraine: developing drugs for acute treatment guidance for industry. https://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM419465.pdf. Published February
2018. Accessed February 1 2019.
6. Oswald JC, Schuster NM. Lasmiditan for the treatment of
acute migraine: a review and potential role in clinical practice.
J Pain Res. 2018;11:2221-2227.
7. Vila-Pueyo M. Targeted 5-HT1F therapies for migraine.
Neurotherapeutics. 2018;15(2):291-303.
8. Kuca Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB.
Lasmiditan is an effective acute treatment for migraine: a phase 3
randomized study. Neurology. 2018;91(24):e2222-e2232.
9. Holland PR, Goadsby PJ. Targeted CGRP small molecule
antagonists for acute migraine therapy. Neurotherapeutics.
2018;15(2):304-312.
10. Dunlaney C. Allergan buys rights to Merck's migraine drugs.
The Wall Street Journal. https://www.wsj.com/articles/allerganbuys-rights-to-mercks-migraine-drugs-1436268370. Published
July 7 2015. Accessed February 10 2019.
11. Kish T. Emerging therapies for patients with difficult-to-treat
migraine. P T. 2018;43(10):616-621.
12. Tepper SJ. Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American headache
society 60th scientific meeting, San Francisco, June 2018.
Headache. 2018;58(suppl 3):276-290.
13. Lipton RB, Coric V, Stovk EG, et al. Rimegepant 75 mg, an
oral calcitonin gene-related peptide antagonist, for the acute
treatment of migraine: two phase 3, double-blind, randomized, placebo-controlled trials. MTIS 2018 digital poster.
https://www.biohavenpharma.com/sites/default/files/documents/Rimegepant-Phase-3-Studies-301-302_MTIS-2018Digital-Poster-Presentation.pdf. Published September 7 2018.
Accessed February 10 2019.
14. Tfelt-Hansen P, Loder E. The emperor's new gepants: are the
effects of the new oral CGRP antagonists clinically meaningful. Headache. 2019;59(1):113-117.
15. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of
administration) for acute migraine attacks in adults: overview of Cochrane reviews. Cochrane Database Syst Rev.
2014;(5):CD009108.
16. Prescribe Right, Pharmaceutical Pipeline Tracker. http://www.
prescriberight.com/pharmaceutical-pipeline-tracker.html.
Published 2019. Accessed February 1 2019.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment https://www.wsj.com/articles/allergan-buys-rights-to-mercks-migraine-drugs-1436268370 https://www.wsj.com/articles/allergan-buys-rights-to-mercks-migraine-drugs-1436268370 https://www.biohavenpharma.com/sites/default/files/documents/Rimegepant-Phase-3-Studies-301-302_MTIS-2018-Digital-Poster-Presentation.pdf https://www.biohavenpharma.com/sites/default/files/documents/Rimegepant-Phase-3-Studies-301-302_MTIS-2018-Digital-Poster-Presentation.pdf https://www.orcid.org/0000-0002-8527-2560 https://www.prescriberight.com/pharmaceutical-pipeline-tracker.html https://www.prescriberight.com/pharmaceutical-pipeline-tracker.html

Hospital Pharmacy - July/August 2019

Table of Contents for the Digital Edition of Hospital Pharmacy - July/August 2019